Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway

Tjitske Kleefstra, Saskia B. Wortmann, Richard J.T. Rodenburg, Ernie M.H.F. Bongers, Kinga Hadzsiev, Cees Noordam, Lambert P. Van Den Heuvel, Willy M. Nillesen, Katalin Hollody, Gabrielle Gillessen-Kaesbach, Martin Lammens, Jan A.M. Smeitink, Ineke Van Der Burgt, Eva Morava*

*Corresponding author for this work
22 Citations (Scopus)


Various syndromes of the Ras-mitogen-activated protein kinase (MAPK) pathway, including the Noonan, Cardio-Facio-Cutaneous, LEOPARD and Costello syndromes, share the common features of craniofacial dysmorphisms, heart defect and short stature. In a subgroup of patients, severe muscle hypotonia, central nervous system involvement and failure to thrive occur as well. In this study we report on five children diagnosed initially with classic metabolic and clinical symptoms of an oxidative phosphorylation disorder. Later in the course of the disease, the children presented with characteristic features of Ras-MAPK pathway-related syndromes, leading to the reevaluation of the initial diagnosis. In the five patients, in addition to the oxidative phosphorylation disorder, disease-causing mutations were detected in the Ras-MAPK pathway. Three of the patients also carried a second, mitochondrial genetic alteration, which was asymptomatically present in their healthy relatives. Did we miss the correct diagnosis in the first place or is mitochondrial dysfunction directly related to Ras-MAPK pathway defects? The Ras-MAPK pathway is known to have various targets, including proteins in the mitochondrial membrane influencing mitochondrial morphology and dynamics. Prospective screening of 18 patients with various Ras-MAPK pathway defects detected biochemical signs of disturbed oxidative phosphorylation in three additional children. We concluded that only a specific, metabolically vulnerable sub-population of patients with Ras-MAPK pathway mutations presents with mitochondrial dysfunction and a more severe, early-onset disease. We postulate that patients with Ras-MAPK mutations have an increased susceptibility, but a second metabolic hit is needed to cause the clinical manifestation of mitochondrial dysfunction.

Original languageEnglish
JournalEuropean Journal of Human Genetics
Issue number2
Pages (from-to)138-144
Number of pages7
Publication statusPublished - 01.02.2011


Dive into the research topics of 'Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway'. Together they form a unique fingerprint.

Cite this